Novartis Investigative Site

Ho Chi Minh City, VNM 700000

1 studies enrolling now · 7 studies all time

What they study most

Asthma, Diffuse Cutaneous Systemic Sclerosis, IgA Nephropathy, Lupus Nephritis, Moderate to Severe Chronic Plaque-Type Psoriasis, Primary IgA Nephropathy, Psoriatic Arthritis

Studies at this site

• A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis — Recruiting now
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy — Running, not enrolling
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients — Completed
• Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis — Stopped early
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis — Completed
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis — Completed